<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Indirect immunofluorescence staining with monoclonal antibody (MoAb) CL203.4 of malignant cells from 269 patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> showed a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> expression of CD54/intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (ICAM-1) </plain></SENT>
<SENT sid="1" pm="."><plain>This marker was expressed by malignant cells of 57 out of 118 patients with <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> and 69 out of 135 with B-lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>On the other hand, CD54 was not detected on malignant cells of 16 patients with T-lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e>, CD54 is preferentially expressed by "stem cell-derived" <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, being detectable on blast cells from almost <z:hpo ids='HP_0000001'>all</z:hpo> patients affected by <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast phase</z:e> or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and by only 34% of patients with de novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>The expression of CD54 did not correlate with any specific myeloid FAB subtype, although three cases of highly undifferentiated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (FAB MO) displayed maximal levels of the antigen </plain></SENT>
<SENT sid="5" pm="."><plain>The expression of CD54 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was significantly associated with that of CD34 and HLA-DR antigens </plain></SENT>
<SENT sid="6" pm="."><plain>In B-lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, CD54 expression appears to correlate with the differentiation stage of malignant cells, since B-origin <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo> and conventional B-<z:hpo ids='HP_0005550'>chronic lymphocytic leukemias</z:hpo> (B-CLL; ie, "dim SIg" CLL) expressed lower levels of CD54 than more mature <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> ("bright SIg" CLL, prolymphocytic <z:hpo ids='HP_0001909'>leukemias</z:hpo>, and lymphoplasmacytic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>). "High-grade" B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (B-NHL) express in general a higher level of CD54 than "low-grade" ones </plain></SENT>
<SENT sid="7" pm="."><plain>This finding in conjunction with the expression of CD54 in <z:hpo ids='HP_0000001'>all</z:hpo> 17 patients with "bright SIg" CLL investigated (characterized by marked organomegaly and poor prognosis) suggest that the differential expression of CD54 in <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> may also relate to their degree of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
</text></document>